Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Namour, F.
Right arrow Articles by Lenfant, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Namour, F.
Right arrow Articles by Lenfant, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 1035-1038
© 2002 The British Society for Antimicrobial Chemotherapy

Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration

F. Namour*, E. Sultan, M. H. Pascual and B. Lenfant

Aventis Pharma, Hoechst Marion Roussel/Romainville, 102 Route de Noisy, 93235 Romainville, France

Received 12 December 2001; returned 26 February 2002; revised 4 March 2002; accepted 13 March 2002.

The penetration of telithromycin (HMR 3647), a novel ketolide antimicrobial, has been assessed in an open, single-dose study in eight healthy male subjects. Following a single, oral, 600 mg dose the mean ratio of the concentration of telithromycin in blister fluid over plasma was 1.38. Significant blister fluid concentrations were maintained up to 24 h post-dose. These results indicate that telithromycin penetrates well into inflammatory extracellular fluid, achieving high and sustained concentrations in this medium.

Keywords: ketolide, telithromycin, HMR 3647, tissue penetration, inflammatory fluid, antimicrobial

* Corresponding author. Tel: +33-1-4991-5807; Fax: +33-1-4991-4842; E-mail: florence.namour{at}aventis.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
N. Kasbekar and P. S. Acharya
Telithromycin: The first ketolide for the treatment of respiratory infections
Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. S. Kuehnel, C. Schurr, K. Lotter, and F. Kees
Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis
J. Antimicrob. Chemother., April 1, 2005; 55(4): 591 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Islinger, R. Bouw, M. Stahl, E. Lackner, P. Zeleny, M. Brunner, M. Muller, H. G. Eichler, and C. Joukhadar
Concentrations of Gemifloxacin at the Target Site in Healthy Volunteers after a Single Oral Dose
Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4246 - 4249.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.